Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Key points – Combination of idelalisib and entospletinib resulted in treatment-emergent pneumonitis, necessitating early study termination. Initial trials of novel combinations should use conservative designs that are focused on safety.